Market News & Trends
Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42 Million
Avadel Pharmaceuticals plc recently announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz, Vazculep,…
Ajinomoto Bio-Pharma Services Introduces AJILITY Fast-Track Platform for Drug Product Manufacturing
Ajinomoto Bio-Pharma Services recently announce the launch of AJILITY, a flexible and agile drug product manufacturing platform, designed to advance….
Bioasis & Chiesi Group Announce Rare Diseases Strategic Alliance
Bioasis Technologies, Inc. and Chiesi Global Rare Diseases recently announced they have entered into a worldwide, exclusive licensing agreement for the….
FDA Approves First & Only Oral Somatostatin Analog for Acromegaly
Chiasma, Inc. recently announced the US FDA approved MYCAPSSA (octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment…
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study
RedHill Biopharma Ltd. recently announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the company’s Clinical Trial Authorization (CTA) application to commence a….
Artelo Biosciences Expands Stony Brook Commercial License Agreement for Development of Lead Cancer, Pain & Inflammation Compounds
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced that it has expanded…
Intra-Cellular Therapies Announces Positive Top-line Results from Phase 1/2 Study
Intra-Cellular Therapies, Inc. recently announced topline results from Study ITI-214-104, a Phase 1/2 translational study of single ascending doses of ITI-214, a novel, selective phosphodiesterase-1…
Aptose Announces FDA Allowance of IND for Phase 1a/b Study
Aptose Biosciences Inc. recently announced the US FDA completed its review of the company’s Investigational New Drug (IND) application and has granted IND allowance for…
Oncology Venture Signs Agreement to Out-License Two Pipeline Assets
Oncology Venture A/S (OV) recently announced it has signed a definitive agreement out-licensing two clinical pipeline assets, LiPlaCis and 2X-111, to Smerud Medical Research International…
Novartis Announces MET inhibitor Approved in Japan for Advanced Non-Small Cell Lung Cancer With METex14
Novartis Pharma KK recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for…
Bormioli Pharma Invests in Type I Glass Vial Production for Injectable Medicines & Vaccines
The global, Covid-19 pandemic emergency has not weakened Bormioli Pharma's determination to keep on investing and supporting its customers. After the acquisition of the German…
Moderna & Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate
Moderna, Inc. and Catalent, Inc. recently announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate…..
Yumanity Therapeutics Announces Strategic Research Collaboration & License Agreement With Merck
Yumanity Therapeutics recently announced it has entered into a strategic research collaboration and license agreement with Merck focused on accelerating….
Mateon & GMP Completed Research & Service Agreement
Mateon Therapeutics, Inc. recently announced that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement entered on….
Esperion & Daiichi Sankyo Europe Announce Amendment to License & Commercial Collaboration Agreement
Esperion recently announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE). ….
AGTC Announces Significant Productivity & Quality Enhancement to Its Proprietary Manufacturing Process
Applied Genetic Technologies Corporation recently provided an update on the continued productivity and quality improvements made in its proprietary manufacturing platform that is….
Provectus Biopharmaceuticals Announces Discovery of Unique PV-10-Induced STING Pathway Mechanism
Provectus recently announce that data from ongoing preclinical study of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) was presented at the American Association for…
Catalent Partners With ViralClear Pharmaceuticals on Potential Treatment for COVID-19
Catalent recently announced it has signed an agreement with ViralClear Pharmaceuticals, Inc. to work on the development of a potential treatment for adults with advanced…
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study
Corbus Pharmaceuticals Holdings, Inc. recently announced the last subject completed their final visit in the company’s Phase 2b JBT101-CF-002 trial of lenabasum for the treatment…
uniQure Announces First Two Patients Treated in Phase 1/2 Clinical Trial
uniQure NV recently announced that the first two patients in the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s disease have been…
